Synergy Pharmaceuticals Inc (SGYP)

2.69
0.04 1.30
NASDAQ : Health Care
Prev Close 2.65
Open 2.66
Day Low/High 2.63 / 2.72
52 Wk Low/High 2.50 / 9.76
Volume 2.54M
Avg Volume 4.22M
Exchange NASDAQ
Shares Outstanding 224.95M
Market Cap 600.63M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Will Allergan's Deal With Tribe Hold Up?

Will Allergan's Deal With Tribe Hold Up?

Answering questions from the biotech mailbag.

SGYP January 2020 Options Begin Trading

Investors in Synergy Pharmaceuticals Inc saw new options become available today, for the January 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 858 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

2 Small Biotechs Under $5 May Be Bargains

2 Small Biotechs Under $5 May Be Bargains

T2 Biosystems and Synergy Pharmaceuticals offer promising prospects at reasonable prices.

Insiders Now Seeing Red With SGYP At New 52-Week Low

In trading on Friday, shares of Synergy Pharmaceuticals Inc touched a new 52-week low of $2.71/share. That's a $4.44 share price drop, or -62.10% decline from the 52-week high of $7.15 set back on 01/31/2017.

Synergy Pharmaceuticals To Present At Upcoming September Investor Conferences

Synergy Pharmaceuticals To Present At Upcoming September Investor Conferences

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present corporate updates at three upcoming investor conferences in New York City during September: Rodman & Renshaw 19 th Annual...

Synergy Pharmaceuticals Secures $300 Million Debt Financing

Synergy Pharmaceuticals Secures $300 Million Debt Financing

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), announced today that the Company has closed on a $300 million debt financing structured as senior secured loans from CRG LP, a healthcare focused investment firm, and its lender...

SGYP: Insiders vs. Shorts

The most recent short interest data was recently released for the 08/15/2017 settlement date, and Synergy Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 10.03 "days to cover" versus the median component at 5.20. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

First Week of SGYP April 2018 Options Trading

Investors in Synergy Pharmaceuticals Inc saw new options begin trading this week, for the April 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results And Business Update

Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for...

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Jim Cramer says investors should step away from these near-term shenanigans and focus on the fundamentals.

3 Biotech Stocks on Readers' Minds

3 Biotech Stocks on Readers' Minds

We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

First Week of SGYP August 18th Options Trading

Investors in Synergy Pharmaceuticals Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Comcast, Synergy Pharmaceuticals, Chipotle, Blackstone Group: 'Mad Money' Lightning Round

Comcast, Synergy Pharmaceuticals, Chipotle, Blackstone Group: 'Mad Money' Lightning Round

Jim Cramer is bullish on Comcast, Synergy Pharmaceuticals, Chipotle, and Blackstone Group, but he's bearish on Sierra Wireless.

Go Inside Amazon's Disruptive Deal for Whole Foods: Cramer's 'Mad Money' Recap (Friday 6/16/17)

Go Inside Amazon's Disruptive Deal for Whole Foods: Cramer's 'Mad Money' Recap (Friday 6/16/17)

Amazon wants to entertain and clothe -- and now feed -- every American. Cramer names the winners and the losers in this deal.

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

Remember the Rules of the Road

Remember the Rules of the Road

Diversification is the only risk management strategy that will work consistently.

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Plus more from the biotechnology world on Wednesday, June 7.

3 Beaten-Down Biotechs That Should Head Up

3 Beaten-Down Biotechs That Should Head Up

Synergy Pharmaceuticals, Trevena and Egalet seem to have worst-case scenarios priced into them.

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Synergy Pharmaceuticals, Bluebird Bio and DBV Technologies were among the biotech stock movers in early trading on Friday.

New 52-Week Low Could Prompt More Insider Buying At SGYP

In trading on Wednesday, shares of Synergy Pharmaceuticals Inc touched a new 52-week low of $3.34/share. That's a $3.81 share price drop, or -53.29% decline from the 52-week high of $7.15 set back on 01/31/2017.

SGYP: Insiders vs. Shorts

The most recent short interest data was recently released for the 05/15/2017 settlement date, and Synergy Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 10.18 "days to cover" versus the median component at 4.71. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Synergy Pharmaceuticals To Present At The Jefferies 2017 Global Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present a corporate update at the Jefferies Global Healthcare Conference in New York City on Thursday, June 8, 2017 at 2:00 p.

Short Interest Moves 20.6% Lower For SGYP

The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 14,132,134 share decrease in total short interest for Synergy Pharmaceuticals Inc , to 54,425,438, a decrease of 20.61% since 04/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

3 Small Biotech Value Plays

3 Small Biotech Value Plays

These stocks will be great stories in the second half of 2017, and are significantly undervalued.

Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for...

Synergy Pharmaceuticals To Present Positive TRULANCE™ (Plecanatide) Phase 3 Data At Digestive Disease Week (DDW) For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the company will present late-breaking data from Phase 3 studies evaluating TRULANCE™ (plecanatide) for the treatment of adults with irritable bowel...